Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellar
NCT03780257Phase 2Completed
- Sponsor
- ProQR Therapeutics
- Start
- Mar 2019
- Primary completion
- Oct 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ultevursen in retinitis pigmentosa (RP) and Usher syndrome type 2A (USH2A) (4 arms), sponsored by ProQR Therapeutics. Primary endpoints: Incidence and severity of ocular adverse events at 24 months and Incidence and severity of non-ocular adverse events at 24 months. Started Mar 2019; status: completed.
02
Drugs
ultevursen
03
Conditions
retinitis pigmentosa (RP)Usher syndrome type 2A (USH2A)
Beyond the preview
Go deeper on NCT03780257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03780257.